10-Q: Helius Medical Technologies Reports Q1 2025 Results Amidst Financial Challenges

Helius Medical Technologies reports a net loss for Q1 2025, faces Nasdaq compliance issues, and continues to pursue strategic alternatives.

Summary

• Helius Medical Technologies reported a net loss of $3.838 million for the three months ended March 31, 2025, compared to a net loss of $2.516 million for the same period in 2024.
• Revenue decreased to $49,000 from $135,000 year-over-year, primarily due to lower U.S. sales of PoNS systems.
• The company's operating loss was $4.011 million, compared to $3.416 million in the prior year.
• As of March 31, 2025, cash and cash equivalents stood at $1.109 million.
• The company is exploring strategic alternatives to maximize stockholder value.
• Helius received notice from Nasdaq regarding non-compliance with minimum bid price and stockholders' equity requirements and has been granted an extension until June 30, 2025, to regain compliance.
• The company completed enrollment in its stroke registrational studies, exceeding the initial target with 128 participants enrolled by December 31, 2024, and is on track to submit for FDA authorization for stroke in the second quarter of 2025, with the plan to achieve FDA authorization by the end of 2025.
• A private placement in April 2025 generated gross proceeds of $1.3 million.
• The company established Revelation Neuro, Inc. to develop a new standard of care for personalized neurorehabilitation.
• The company is pursuing commercial insurance coverage for PoNS within the Durable Medical Equipment benefit category.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While there are some positive developments, such as the first reimbursement payment and progress in clinical trials, the company faces significant financial challenges, including increasing losses, declining revenue, and Nasdaq compliance issues. The overall sentiment is cautiously negative.

Positives

• Helius received its first reimbursement payment from a major healthcare provider, Anthem Blue Cross Blue Shield, for its PoNS Device.
• The company has completed and far exceeded the initial 90-subject target enrollment for its stroke registrational program enrolling 128 participants by December 31, 2024.
• The company has been granted an extension until June 30, 2025 to regain compliance with Nasdaq listing requirements.
• The company established Revelation Neuro, Inc. to develop a new standard of care for personalized neurorehabilitation.
• The company partnered with Lovell Government Services to make the PoNS device available to federal healthcare systems.

Negatives

• Helius reported a net loss of $3.838 million for Q1 2025, an increase from the $2.516 million loss in Q1 2024.
• Revenue decreased significantly to $49,000 from $135,000 year-over-year.
• The company is facing Nasdaq compliance issues related to minimum bid price and stockholders' equity requirements.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern.
• The company's operating loss was $4.011 million, compared to $3.416 million in the prior year.

Risks

• The company's ability to continue as a going concern is uncertain, dependent on raising additional capital and achieving profitable operations.
• Failure to regain compliance with Nasdaq listing requirements could result in delisting, negatively impacting the stock price and liquidity.
• Global economic conditions, including inflation, supply chain disruptions, and geopolitical conflicts, could adversely affect the company's business and access to capital.
• The company's success depends on obtaining broad coverage and reimbursement for PoNS Therapy from government and private payers, which is expected to take at least 24 months.
• Clinical trials may not be successful, and regulatory approvals may not be obtained, hindering the commercialization of PoNS for new indications.

Future Outlook

The company expects to continue to incur significant expenses and operating losses for the foreseeable future and believes that its existing capital resources, as well as the $1.2 million net proceeds from the sales of promissory notes and issuance of shares in April of 2025 along with $3.4 million net proceeds from the exercise of the Existing Warrants by the Holders and $0.1 million net proceeds from the issuance and sale under the ATM in January of 2025 will be sufficient to fund its operations into the second quarter of 2025, but it will be required to seek additional funding through the sale of equity or debt financing to continue to fund its operations thereafter.

Management Comments

• Although we believe our plan will be sufficient to enable us to regain compliance, no assurance can be provided that Nasdaq will ultimately accept our plan or that we will ultimately regain compliance with the Minimum Bid Price Requirement.
• We are pursuing commercial insurance coverage for PoNS within the Durable Medical Equipment benefit category.
• We also intend to provide broad access and reimbursement for the PoNS Therapy over time through commercial insurers.

Industry Context

The neurotechnology industry is focused on developing innovative solutions for neurological disorders. Helius Medical Technologies competes with other companies in the neuromodulation and neurorehabilitation space. The company's success depends on its ability to demonstrate the efficacy and cost-effectiveness of its PoNS device and secure reimbursement from payers.

Comparison to Industry Standards

• It is difficult to compare Helius Medical Technologies directly to industry standards due to its unique product and focus.
• However, other companies in the neuromodulation space, such as NeuroPace and LivaNova, have achieved significant revenue growth and market capitalization.
• Helius's revenue of $49,000 for Q1 2025 is significantly lower than the revenue of these larger companies.
• The company's ability to secure reimbursement and expand its market reach will be critical to its long-term success.

Stakeholder Impact

• Shareholders face the risk of further stock dilution and potential delisting from Nasdaq.
• Employees face uncertainty due to the company's financial challenges and potential strategic alternatives.
• Customers may be affected by the company's ability to continue providing PoNS Therapy and support.
• Suppliers and creditors face the risk of non-payment if the company's financial situation deteriorates.

Next Steps

• Submit for FDA authorization for stroke in the second quarter of 2025.
• Continue to pursue commercial insurance coverage for PoNS within the Durable Medical Equipment benefit category.
• Regain compliance with Nasdaq listing requirements by June 30, 2025.
• Continue to evaluate options with respect to potential strategic alternatives.

Key Dates

Keywords

PoNS, Helius Medical Technologies, Neuromodulation, Stroke, Gait deficit, Balance deficit, Nasdaq, FDA, Reimbursement, Clinical trials, Financial results